Nanobiotix: NANOBIOTIX Provides First Quarter Operational and Financial Update
On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3
Source: finanznachrichten.de